Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast...
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial
About this item
Full title
Author / Creator
Publisher
Poland: Sciendo
Journal title
Language
English
Formats
Publication information
Publisher
Poland: Sciendo
Subjects
More information
Scope and Contents
Contents
The CDK4/6 inhibitor, ribociclib in combination with endocrine therapy significantly improved progression-free survival in the first line setting in post-menopausal patients with HR+/HER2- advanced breast cancer (ABC) in a pivotal phase 3, placebo-controlled trial (MONALEESA-2) and demonstrated superior overall survival in premenopausal patients wi...
Alternative Titles
Full title
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_6ce42c9b31d146e5b6622fa9c89a8d7c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6ce42c9b31d146e5b6622fa9c89a8d7c
Other Identifiers
ISSN
1581-3207,1318-2099
E-ISSN
1581-3207,0485-893X
DOI
10.2478/raon-2022-0020
